Jun 07, 2021 / 02:00PM GMT
Meg Tirrell -
(technical difficulty)
Chairman and CEO of Merck. He's been there, of course, since 1992 in this role since 2011. Of course, in February, which was the last time that Ken and I got to speak, they announced his retirement as CEO, although he'll remain Executive Chairman for some period of time. Of course, as CEO of Merck, Ken has overseen the rise of KEYTRUDA. At the beginning of his tenure as CEO, he told me there was a pressure on the industry to cut research and development. That was a pressure that he resisted.
I'm going to hand it over to Ken Frazier now for his presentation. And I also encourage everybody to put your questions in the Q&A tab, and we'll get to those after the presentation. Ken, over to you.
Kenneth C. Frazier - Merck & Co., Inc. - CEO & Chairman
Okay. Good morning all, and thank you, Meg, for that introduction. I also want to thank the Chief Executives for Corporate Purpose, along with the Biopharma Sustainability Roundtable, for hosting this forum today.
Just 3 years ago, I joined many of you
Merck & Co Inc at CECP CEO Investor Forum (Virtual) Transcript
Jun 07, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers